Romano Brothers AND Company Sells 508 Shares of Johnson & Johnson (NYSE:JNJ)

Romano Brothers AND Company trimmed its holdings in Johnson & Johnson (NYSE:JNJ) by 1.4% in the first quarter, according to the company in its most recent filing with the SEC. The fund owned 36,719 shares of the company’s stock after selling 508 shares during the quarter. Romano Brothers AND Company’s holdings in Johnson & Johnson were worth $5,809,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in JNJ. Saratoga Research & Investment Management boosted its holdings in Johnson & Johnson by 1.0% during the 1st quarter. Saratoga Research & Investment Management now owns 439,519 shares of the company’s stock valued at $69,528,000 after acquiring an additional 4,377 shares during the period. Grimes & Company Inc. boosted its stake in shares of Johnson & Johnson by 2.3% during the first quarter. Grimes & Company Inc. now owns 97,925 shares of the company’s stock valued at $15,491,000 after purchasing an additional 2,210 shares during the period. WoodTrust Financial Corp grew its holdings in shares of Johnson & Johnson by 10.9% in the first quarter. WoodTrust Financial Corp now owns 91,970 shares of the company’s stock worth $14,549,000 after purchasing an additional 9,033 shares during the last quarter. Griffin Asset Management Inc. increased its stake in shares of Johnson & Johnson by 0.5% in the first quarter. Griffin Asset Management Inc. now owns 79,488 shares of the company’s stock worth $12,574,000 after buying an additional 400 shares during the period. Finally, Toth Financial Advisory Corp raised its holdings in Johnson & Johnson by 1.8% during the 1st quarter. Toth Financial Advisory Corp now owns 62,847 shares of the company’s stock valued at $9,942,000 after buying an additional 1,091 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the stock. The Goldman Sachs Group assumed coverage on shares of Johnson & Johnson in a research report on Thursday, May 30th. They issued a “neutral” rating and a $160.00 price objective on the stock. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Sunday. Royal Bank of Canada reiterated an “outperform” rating and issued a $175.00 price objective on shares of Johnson & Johnson in a research report on Monday, June 17th. Morgan Stanley decreased their target price on Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a report on Wednesday, April 17th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a report on Thursday, June 20th. Eight research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average target price of $174.07.

Johnson & Johnson Trading Up 0.2 %

NYSE:JNJ opened at $146.16 on Monday. The firm has a market capitalization of $351.76 billion, a P/E ratio of 9.11, a PEG ratio of 2.43 and a beta of 0.53. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.17 and a quick ratio of 0.94. Johnson & Johnson has a one year low of $143.13 and a one year high of $175.97. The company’s 50-day simple moving average is $148.14 and its 200 day simple moving average is $154.05.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 EPS for the quarter, topping analysts’ consensus estimates of $2.64 by $0.07. The firm had revenue of $21.38 billion for the quarter, compared to analysts’ expectations of $21.39 billion. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. The business’s revenue for the quarter was up 2.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.68 EPS. As a group, analysts forecast that Johnson & Johnson will post 10.62 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st were given a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 3.39%. The ex-dividend date of this dividend was Monday, May 20th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.19. Johnson & Johnson’s payout ratio is currently 30.92%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.